Stock ALRN AILERON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Delayed Nasdaq
Other stock markets
 03:52:57 2024-05-28 pm EDT 		5-day change 1st Jan Change
3.365 USD -4.13% Intraday chart for Aileron Therapeutics, Inc. -10.74% +10.38%
May. 03 Aileron Therapeutics Closes Direct Offering of Shares, Warrants MT
May. 01 Transcript : Aileron Therapeutics, Inc. - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
AQ
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
AQ
Aileron Therapeutics Closes Direct Offering of Shares, Warrants
MT
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
AQ
Transcript : Aileron Therapeutics, Inc. - Special Call
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
AQ
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
AQ
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
CI
Ladenburg Thalmann Adjusts Aileron Therapeutics Price Target to $19 From $9, Maintains Buy Rating
MT
Aileron Therapeutics : Corporate Presentation April 2024
PU
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Aileron Therapeutics : Management Change/Compensation - Form 8-K
PU
Aileron Therapeutics, Inc. Announces CFO Changes
CI
Aileron Therapeutics, Inc. Announces Board Changes
CI
Aileron Therapeutics Names Brian Windsor as CEO
MT
Aileron Therapeutics Announces CEO Transition
AQ
Aileron Therapeutics, Inc. Announces Appointment of Brian Windsor as President and to the Board of Directors
CI
Aileron Therapeutics, Inc. Announces CEO Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALRN Stock
  4. News Aileron Therapeutics, Inc.